Cell Discovery (Jun 2024)

Single-cell sequencing depicts tumor architecture and empowers clinical decision in metastatic conjunctival melanoma

  • Hanhan Shi,
  • Hao Tian,
  • Tianyu Zhu,
  • Qili Liao,
  • Chang Liu,
  • Peng Yuan,
  • Yongyun Li,
  • Jie Yang,
  • Chunyan Zong,
  • Shichong Jia,
  • Jing Ruan,
  • Shengfang Ge,
  • Renbing Jia,
  • Peiwei Chai,
  • Shiqiong Xu,
  • Xianqun Fan

DOI
https://doi.org/10.1038/s41421-024-00683-y
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Conjunctival melanoma (CoM) is a potentially devastating tumor that can lead to distant metastasis. Despite various therapeutic strategies for distant metastatic CoM, the clinical outcomes remain unfavorable. Herein, we performed single-cell RNA sequencing (scRNA-seq) of 47,017 cells obtained from normal conjunctival samples (n = 3) and conjunctival melanomas (n = 7). Notably, we noticed a higher abundance of cancer-associated fibroblasts (CAFs) in tumor microenvironment (TME), correlated with enhanced angiogenic capacity and increased VEGFR expression in distal metastatic CoM. Additionally, we observed a significant decrease in the proportion of total CD8+ T cells and an increase in the proportion of naive CD8+ T cells, contributing to a relatively quiescent immunological environment in distal metastatic CoM. These findings were confirmed through the analyses of 70,303 single-cell transcriptomes of 7 individual CoM samples, as well as spatially resolved proteomes of an additional 10 samples of CoMs. Due to the increase of VEGFR-mediated angiogenesis and a less active T cell environment in distal metastatic CoMs, a clinical trial (ChiCTR2100045061) has been initiated to evaluate the efficacy of VEGFR blockade in combination with anti-PD1 therapy for patients with distant metastatic CoM, showing promising tumor-inhibitory effects. In conclusion, our study uncovered the landscape and heterogeneity of the TME during CoM tumorigenesis and progression, empowering clinical decisions in the management of distal metastatic CoM. To our knowledge, this is the initial exploration to translate scRNA-seq analysis to a clinical trial dealing with cancer, providing a novel concept by accommodating scRNA-seq data in cancer therapy.